Apixa CCP Dosage/Direction for Use

Recommended Dose: Adult: Prevention of venous thromboembolic events (VTE): elective hip or knee replacement surgery: The recommended dose is 2.5 mg twice daily. The initial dose should be administered at least 12-24 hours after surgery.
In patients undergoing hip replacement surgery, the recommended duration of treatment is 32 to 38 days.
In patients undergoing knee replacement surgery, the recommended duration of treatment is 10 to 14 days.
Prevention of stroke and systemic embolism: non-valvular atrial fibrillation: The recommended dose is 5 mg twice daily.
In patients at least 2 of the following characteristics, age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, the recommended dose is 2.5 mg twice daily.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE): The recommended dose is 10 mg twice daily for 7 days, followed by 5 mg twice daily.
Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE): The recommended dose is 2.5 mg twice daily after at least 6 months of treatment for DVT or PE.
Renal impairment: Prevention of venous thromboembolic events (VTE): elective hip or knee replacement surgery: No dosage adjustment is necessary in patients with mild, moderate or severe (creatinine clearance 15 to 29 mL/min) renal impairment.
Prevention of stroke and systemic embolism: non-valvular atrial fibrillation: No dosage adjustment is necessary in patients with creatinine clearance 15 to 29 mL/min.
Treatment of venous thromboembolic events (VTE): No dosage adjustment is necessary in patients with mild, moderate or severe (creatinine clearance 15 to 29 mL/min) renal impairment.
Hepatic impairment: No dosage adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A). Because of limited experience, the manufacturer states that dosage recommendations cannot be provided in patients with moderate hepatic impairment (Child-Pugh class B). The use of apixaban is not recommended in patients with severe hepatic impairment (Child-Pugh class C).
Elderly: Prevention of venous thromboembolic events (VTE): elective hip or knee replacement surgery: No dose adjustment required.
Prevention of stroke and systemic embolism: non-valvular atrial fibrillation: If patient is ≥80 years of age and either weighs ≤60 kg or has a serum creatinine ≥1.5 mg/dL, then reduce dose to 2.5 mg twice daily.
Treatment of venous thromboembolic events (VTE): No dose adjustment required.
Mode of Administration: APIXA CCP is administered orally twice daily without regard to food.